MYGN Stock Analysis: Myriad Genetics | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 399m USD | 12M Return: -40% | US62855J1043 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.08M
Qual. Beats: -1
Rev. Trend: 72.7%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Myriad Genetics is a U.S.-based molecular diagnostics and precision medicine company founded in 1991 and headquartered in Salt Lake City, Utah. It develops and commercializes DNA- and RNA-based tests across three primary areas: oncology, womens health, and pharmacogenomics. Its oncology portfolio includes hereditary cancer risk assessment (MyRisk), germline and tumor companion diagnostics used to guide therapy selection (BRACAnalysis CDx and MyChoice CDx), prostate and breast cancer prognostic tests (Prolaris and EndoPredict), and a broad genomic profiling assay (Precise Tumor). Womens health offerings span non-invasive prenatal screening (Prequel), carrier screening (Foresight), and an early fetal gender test (SneakPeek). Its pharmacogenomics line is anchored by GeneSight, a mental health medication selection test.
The company maintains research and licensing collaborations with several major institutions and partners, including Illumina, MD Anderson Cancer Center, Mayo Clinic, and Eurobio Scientific. As a small-cap healthcare name in the GICS Biotechnology sub-industry, Myriad operates in the personalized medicine and companion diagnostics segment, an area where insurers and regulators increasingly tie reimbursement to clinical utility evidence.
- GeneSight test volume growth lifts pharmacogenomics segment revenue
- SneakPeek and prenatal screening expand womens health diagnostics
- Reimbursement pressure threatens hereditary cancer test margins
| Net Income: -112.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA 5.18 > 1.0 |
| NWC/Revenue: 19.63% < 20% (prev 10.13%; Δ 9.49% < -1%) |
| CFO/TA 0.01 > 3% & CFO 7.70m > Net Income -112.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (94.8m) vs 12m ago 2.49% < -2% |
| Gross Margin: 68.83% > 18% (prev 70.44%; Δ -1.61% > 0.5%) |
| Asset Turnover: 122.6% > 50% (prev 123.0%; Δ -0.41% > 0%) |
| Interest Coverage Ratio: -5.82 > 6 (EBIT TTM -95.4m / Interest Expense TTM 16.4m) |
| A: 0.25 (Total Current Assets 289.0m - Total Current Liabilities 130.7m) / Total Assets 638.9m |
| B: -1.88 (Retained Earnings -1.20b / Total Assets 638.9m) |
| C: -0.14 (EBIT TTM -95.4m / Avg Total Assets 658.1m) |
| D: 0.91 (Book Value of Equity 303.9m / Total Liabilities 335.0m) |
| Altman-Z'' = -4.52 = D |
| DSRI: 0.83 (Receivables 109.5m/137.0m, Revenue 806.6m/832.9m) |
| GMI: 1.02 (GM 70.44% / 68.83%) |
| AQI: 0.88 (AQ_t 0.30 / AQ_t-1 0.34) |
| SGI: 0.97 (Revenue 806.6m / 832.9m) |
| TATA: -0.19 (NI -112.6m - CFO 7.70m) / TA 638.9m) |
| Beneish M = -3.26 (Cap -4..+1) = AA |
As of October 05, 2026, the stock is trading at USD 4.54 with a total of 2,257,987 shares traded. Over the past week, the price has changed by +8.87%, over one month by +40.56%, over three months by -24.21% and over the past year by -39.95%.
Current recommended Stop Loss: 4.10 (which is 9.7% or 1.8 ATR below the current price).
Myriad Genetics has received a consensus analysts rating of 3.33. Therefore, it is recommended to hold MYGN.
- StrongBuy: 3
- Buy: 3
- Hold: 6
- Sell: 2
- StrongSell: 1
| Analysts Target Price | 3.4 | -25.8% |
P/E Forward = 54.0541
P/S = 0.4945
P/B = 1.2621
P/EG = 1.4001
Revenue TTM = 806.6m USD
EBIT TTM = -95.4m USD
EBITDA TTM = -45.2m USD
Long Term Debt = 120.7m USD (from longTermDebt, last quarter)
Short Term Debt = 7.30m USD (from shortTermDebt, last quarter)
Debt = 300.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 89.8m
Net Debt = 185.1m USD (calculated: Debt 300.3m - CCE 115.2m)
Enterprise Value = 584.0m USD (398.9m + Debt 300.3m - CCE 115.2m)
Interest Coverage Ratio = -5.82 (Ebit TTM -95.4m / Interest Expense TTM 16.4m)
EV/FCF = -67.90x (Enterprise Value 584.0m / FCF TTM -8.60m)
FCF Yield = -1.47% (FCF TTM -8.60m / Enterprise Value 584.0m)
FCF Margin = -1.07% (FCF TTM -8.60m / Revenue TTM 806.6m)
Net Margin = -13.96% (Net Income TTM -112.6m / Revenue TTM 806.6m)
Gross Margin = 68.83% ((Revenue TTM 806.6m - Cost of Revenue TTM 251.4m) / Revenue TTM)
Gross Margin QoQ = 66.60% (prev 68.66%)
Tobins Q-Ratio = 0.91 (Enterprise Value 584.0m / Total Assets 638.9m)
Interest Expense / Debt = 5.46% (Interest Expense 16.4m / Debt 300.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -75.4m (EBIT -95.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.21 (Total Current Assets 289.0m / Total Current Liabilities 130.7m)
Debt / Equity = 0.99 (Debt 300.3m / totalStockholderEquity, last quarter 303.9m)
Debt / EBITDA = -4.10 (negative EBITDA) (Net Debt 185.1m / EBITDA -45.2m)
Debt / FCF = -21.52 (negative FCF - burning cash) (Net Debt 185.1m / FCF TTM -8.60m)
Total Stockholder Equity = 345.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -17.11% (Net Income -112.6m / Total Assets 638.9m)
RoE = -32.59% (Net Income TTM -112.6m / Total Stockholder Equity 345.5m)
RoCE = -20.46% (EBIT -95.4m / Capital Employed (Equity 345.5m + L.T.Debt 120.7m))
RoIC = -15.86% (negative operating profit) (NOPAT -75.4m / Invested Capital 475.2m)
WACC = 5.57% (E(398.9m)/V(699.2m) * Re(6.51%) + D(300.3m)/V(699.2m) * Rd(5.46%) * (1-Tc(0.21)))
Discount Rate = 6.51% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.61 | Cagr: 2.39%
[DCF] Fair Price = unknown (Cash Flow -8.60m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.20 | # QB: -1
Revenue Correlation: 72.70 | Revenue CAGR: 3.56% | SUE: -3.17 | # QB: -1
EPS current Quarter (2026-09-30): EPS=-0.21 | Chg30d=-28.02% | Revisions=-73% | Analysts=9
EPS current Year (2026-12-31): EPS=-0.75 | Chg30d=-9.25% | Revisions=-75% | GrowthEPS=-1350.3% | GrowthRev=-5.7%
EPS next Year (2027-12-31): EPS=-0.57 | Chg30d=-37.89% | Revisions=-62% | GrowthEPS=+23.6% | GrowthRev=+5.6%
[Analyst] Revisions Ratio: -88% (up=0, down=22)